Exploratory biomarker analysis of phase 3 ASTRUM-005 study: Serplulimab versus placebo plus chemotherapy for extensive-stage small cell lung cancer

被引：1
|
作者：
Cheng, Ying
Han, Liang
Wu, Lin
Chen, Jun
Sun, Hongmei
Wen, Guilan
Ji, Yinghua
Zimina, Anastasia
Shi, Jianhua
Pan, Zhijie
Shi, Jinsheng
Wang, Xicheng
Yang, Fang
Yang, Xinyi
Chen, Mengkai
Zhong, Shiqi
Wang, Qingyu
Li, Jing
Cheng, Jiancheng
Ling, Chen
Shan, Yongqiang
Zhu, Jun
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6390
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6390
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
    Reck, Martin
    Luft, Alexander
    Szczesna, Aleksandra
    Havel, Libor
    Kim, Sang-We
    Akerley, Wallace
    Pietanza, Maria Catherine
    Wu, Yi-long
    Zielinski, Christoph
    Thomas, Michael
    Felip, Enriqueta
    Gold, Kathryn
    Horn, Leora
    Aerts, Joachim
    Nakagawa, Kazuhiko
    Lorigan, Paul
    Pieters, Anne
    Sanchez, Teresa Kong
    Fairchild, Justin
    Spigel, David
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3740 - +
  • [22] Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing
    Shao, Taihang
    Zhao, Mingye
    Liang, Leyi
    Tang, Wenxi
    BIODRUGS, 2023, 37 (03) : 421 - 432
  • [23] Serplulimab monotherapy in extensive-stage small-cell lung cancer with brain metastasis: a case report
    Xiang, Xudong
    Li, Heng
    Lei, Bao
    Chen, Benchao
    Li, Gaofeng
    IMMUNOTHERAPY, 2024, 16 (08) : 521 - 527
  • [24] Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC
    Rudin, Charles M.
    Ryun Kim, Hye
    Navarro, Alejandro
    Gottfried, Maya
    Peters, Solange
    Csoszi, Tibor
    Kaur Cheema, Parneet
    Rodriguez-Abreu, Delvys
    Wollner, Mira
    Chih-Hsin Yang, James
    Mazieres, Julien
    Kato, Terufumi
    Peter Kalemkerian, Gregory
    Dettman, Elisha
    Edmondson, Mackenzie
    Vajdi, Amir
    Loboda, Andrey
    Edmond El-Osta, Hazem
    Zhao, Bin
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
    Horn, L.
    Mansfield, A. S.
    Szczesna, A.
    Havel, L.
    Krzakowski, M.
    Hochmair, M. J.
    Huemer, F.
    Losonczy, G.
    Johnson, M. L.
    Nishio, M.
    Reck, M.
    Mok, T.
    Lam, S.
    Shames, D. S.
    Liu, J.
    Ding, B.
    Lopez-Chavez, A.
    Kabbinavar, F.
    Lin, W.
    Sandler, A.
    Liu, S. V.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23): : 2220 - 2229
  • [26] A PHASE 2 STUDY OF TORIPALIMAB PLUS ANLOTINIB AS MAINTENANCE THERAPY IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER
    Lv, Dongqing
    Wu, Guixian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A497 - A497
  • [27] Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial
    Cheng, Ying
    Chen, Jianhua
    Zhang, Wei
    Xie, Chao
    Hu, Qun
    Zhou, Ningning
    Huang, Chun
    Wei, Shihong
    Sun, Hong
    Li, Xingya
    Yu, Yan
    Lai, Jinhuo
    Yang, Huaping
    Fang, Haohui
    Chen, Hualin
    Zhang, Peng
    Gu, Kangsheng
    Wang, Qiming
    Shi, Jianhua
    Yi, Tienan
    Xu, Xingxiang
    Ye, Xianwei
    Wang, Daqing
    Xie, Conghua
    Liu, Chunling
    Zheng, Yulong
    Lin, Daren
    Zhuang, Wu
    Lu, Ping
    Yu, Guohua
    Li, Jinzhang
    Gu, Yuhai
    Li, Baolan
    Wu, Rong
    Jiang, Ou
    Wang, Zaiyi
    Wu, Guowu
    Lin, Haifeng
    Zhong, Diansheng
    Xu, Yanhua
    Shu, Yongqian
    Wu, Di
    Chen, Xingwu
    Wang, Jie
    Wang, Minghui
    Yang, Runxiang
    NATURE MEDICINE, 2024, 30 (10) : 1819 - 1822
  • [28] Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China
    Long, Yunchun
    Wang, Hao
    Xie, Xianhai
    Li, Junlin
    Xu, Yuan
    Zhou, Yujie
    BMJ OPEN, 2024, 14 (04):
  • [29] A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)
    Zhou, Caicun
    Hu, Yanping
    Arkania, Ekaterine
    Kilickap, Saadettin
    Ying, Kejing
    Xu, Fei
    Wu, Lin
    Wang, Xiang
    Viguro, Maksym
    Makharadze, Tamta
    Sun, Hongmei
    Luo, Feng
    Shi, Jianhua
    Zang, Aimin
    Pan, Yueyin
    Chen, Zhendong
    Jia, Zhongyao
    Kuchava, Vladimer
    Lu, Ping
    Zhang, Ling
    Cheng, Ying
    Kang, Wenying
    Wang, Qingyu
    Yu, Haoyu
    Li, Jing
    Zhu, Jun
    CANCER CELL, 2024, 42 (02) : 198 - 208.e3
  • [30] Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China
    Kang, Shuo
    Liu, Huanlong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (09) : 1081 - 1088
12345